Feasibility and Efficacy of Cell-Free Ascites Reinfusion Therapy for Pseudomyxoma Peritonei: A Single-Center, Retrospective Study
Funding: This work was supported in part by Grants-in-Aid for Research from the National Center for Global Health and Medicine (23A-3001).
ABSTRACT
Introduction
Limited treatments are available for the highly mucinous Pseudomyxoma Peritonei (PMP)-related ascites. This study assessed the feasibility and efficacy of cell-free ascites reinfusion therapy (CART) for PMP-related ascites.
Methods
Patients with PMP who underwent CART between 2017 and 2021 were included. We retrospectively collected clinical data and compared pre- and post-CART clinical features and symptoms.
Results
Nine patients with PMP underwent 12 CART sessions. A wild-bore chest tube was used in 25% (3/12) of sessions, with no severe complications. Abdominal pain and food intake improved in 92% (11/12) and 42% (5/12) of sessions, respectively (median decrease in weight, −4.4 kg [p = 0.02]). Serum albumin and creatinine levels did not change significantly (p = 0.280 vs. p > 0.500). Mild fever occurred during or after CART in 67% (9/12) of sessions; severe complications were not observed.
Conclusion
CART may be a relatively safe and affordable treatment for PMP-related ascites.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request. The data are not publicly available due to privacy or ethical restrictions.
